Galmed Net Invested Capital vs Long Term Debt Analysis
| GLMD Stock | USD 2.75 0.05 1.79% |
Galmed Pharmaceuticals financial indicator trend analysis is much more than just examining Galmed Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galmed Pharmaceuticals is a good investment. Please check the relationship between Galmed Pharmaceuticals Net Invested Capital and its Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
Net Invested Capital vs Long Term Debt
Net Invested Capital vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galmed Pharmaceuticals Net Invested Capital account and Long Term Debt. At this time, the significance of the direction appears to have very week relationship.
The correlation between Galmed Pharmaceuticals' Net Invested Capital and Long Term Debt is 0.22. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Galmed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Galmed Pharmaceuticals' Net Invested Capital and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Galmed Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Invested Capital i.e., Galmed Pharmaceuticals' Net Invested Capital and Long Term Debt go up and down completely randomly.
Correlation Coefficient | 0.22 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Long Term Debt
Long-term debt is a debt that Galmed Pharmaceuticals has held for over one year. Long-term debt appears on Galmed Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Galmed Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from Galmed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Sales General And Administrative To Revenue is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.25, whereas Issuance Of Capital Stock is forecasted to decline to about 5.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 562K | 297K | 375K | 747.7K | Net Interest Income | 519K | 275K | 745K | 775.1K |
Galmed Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Galmed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Galmed Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 1.4M | 1.4M | 1.6M | 1.7M | 230.8K | 219.3K | |
| Total Assets | 77.1M | 52.4M | 36.6M | 16.6M | 16.6M | 15.8M | |
| Other Current Liab | 892K | 935K | 966K | 1.0M | 830K | 673.0K | |
| Total Current Liabilities | 6.9M | 8.0M | 5.9M | 3.1M | 2.8M | 4.0M | |
| Total Stockholder Equity | 69.9M | 44.2M | 30.5M | 13.4M | 13.9M | 13.2M | |
| Property Plant And Equipment Net | 709K | 570K | 551K | 337K | 125K | 118.8K | |
| Net Debt | (15.6M) | (6.7M) | (2.7M) | (2.0M) | (2.8M) | (3.0M) | |
| Retained Earnings | (106.9M) | (135.7M) | (168.2M) | (186.0M) | (193.0M) | (183.3M) | |
| Accounts Payable | 6.0M | 7.0M | 4.9M | 2.6M | 1.9M | 3.2M | |
| Cash | 15.9M | 6.9M | 2.9M | 2.0M | 2.9M | 2.7M | |
| Non Current Assets Total | 709K | 570K | 551K | 1.8M | 3.4M | 3.6M | |
| Cash And Short Term Investments | 75.5M | 50.9M | 34.8M | 13.8M | 12.6M | 12.0M | |
| Net Receivables | 827K | 812K | 1.1M | 124K | 165K | 156.8K | |
| Liabilities And Stockholders Equity | 77.1M | 52.4M | 36.6M | 16.6M | 16.6M | 15.8M | |
| Other Current Assets | 28.1M | 925K | 1.2M | 668K | 432K | 410.4K | |
| Other Stockholder Equity | 176.7M | 179.5M | 198.8M | 200.1M | 207.1M | 135.2M | |
| Total Liab | 7.3M | 8.2M | 6.1M | 3.1M | 2.8M | 4.4M | |
| Property Plant And Equipment Gross | 709K | 570K | 551K | 1.3M | 1.1M | 678.5K | |
| Total Current Assets | 76.4M | 51.8M | 36.1M | 14.7M | 13.2M | 12.6M | |
| Accumulated Other Comprehensive Income | 35K | 272K | (171K) | (745K) | (454K) | (431.3K) | |
| Property Plant Equipment | 194K | 709K | 570K | 337K | 387.6K | 519.1K | |
| Net Tangible Assets | 15.8M | 87.9M | 69.9M | 44.2M | 50.8M | 38.5M | |
| Short Term Investments | 59.6M | 43.9M | 31.9M | 11.8M | 9.8M | 9.3M | |
| Net Invested Capital | 69.9M | 44.2M | 30.5M | 13.4M | 13.9M | 13.2M | |
| Net Working Capital | 69.5M | 43.8M | 30.2M | 11.6M | 10.5M | 10.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.